Browsing Tag
Zydus Lifesciences
92 posts
Torrent Pharma (NSE: TORNTPHARM) enters GLP-1 market with Sembolic and Semalix as over 40 rivals chase semaglutide patent expiry windfall
Torrent Pharmaceuticals launches India's first generic oral semaglutide alongside injectable Sembolic as GLP-1 patent expires. What the pricing and strategy mean. Read more.
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
Zydus Lifesciences (NSE: ZYDUSLIFE) wins NMPA approval for Desidustat in China, unlocking access to 120 million CKD patients
Zydus Lifesciences' novel oral drug Desidustat receives China NMPA approval for CKD anaemia, unlocking a market of 120 million patients. Read the strategic analysis.
Zydus Lifesciences stock edges higher as Sentynl faces FDA CRL for CUTX-101
Zydus Lifesciences’ U.S. unit Sentynl received an FDA Complete Response Letter for CUTX-101. Find out why investors remain optimistic despite regulatory delays.
Can Indian biosimilar makers dominate ophthalmology markets after Eylea patent expiries?
With Eylea patents expiring, Indian biosimilar makers are eyeing global ophthalmology markets. Find out who’s leading and what’s next.
Zydus Medtech brings Brazil’s breakthrough heart valve tech to India and Europe in global expansion move
Zydus Medtech signs global licensing deal with Braile Biomedica to commercialise next-gen TAVI heart valve tech across India and Europe. Read more.
Zydus Lifesciences, EaseMyTrip, and JTL Industries slump as Indian equities face renewed volatility
Zydus Lifesciences, EaseMyTrip and JTL Industries led the top stock losers in India on April 16, as markets corrected sharply on macro concerns. Read the full analysis.
Zydus wins FDA nod for DMD drug Jaythari—what it means for rare disease treatment and its stock
Find out how Zydus Lifesciences is expanding rare disease care and investor value with USFDA-approved Jaythari tablets for Duchenne muscular dystrophy.
Zydus Lifesciences enters $1.09bn prostate cancer drug market with USFDA green light
Zydus Lifesciences gains USFDA approval for Apalutamide Tablets, 60 mg, expanding its oncology generics portfolio. Find out what this means for investors.